Tacrolimus

CAS 104987-11-3 19 current records 3 historicalSmall Molecule

Who holds supplier records for Tacrolimus? 19 organisations hold a current record for Tacrolimus: an active US FDA Type II Drug Master File or a CEP. A further 3 organisations have only historical (inactive) DMF filings. 10 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: China (6), India (4), Slovenia (1), Netherlands (1) and 4 other countries (4); not recorded for 3.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Tacrolimus: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/tacrolimus

Reading the evidence

  • 19 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 6 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Tacrolimus expires 30 Aug 2028. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (19)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Tacrolimus. Country is the organisation's recorded country, not necessarily the manufacturing site.

China6India4Slovenia1Netherlands1Canada1Japan1South1Spain1Country not recorded for 3
  • Biocon Limited
    Active DMF 39573, 18442, 23365 · latest filing Mar 2024
    IndiaCEP
  • CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTD
    Active DMF 18985, 38310 · latest filing Apr 2023
    CEP Company GMP cert on record
  • CONCORD BIOTECH LTD
    Active DMF 18908, 34491 · latest filing Jan 2020
    IndiaCEP Company GMP cert on record
  • Lek Pharmaceuticals D.D.
    Active DMF 19979, 34063 · latest filing Aug 2020
    SloveniaCEP Company GMP cert on record
  • HISUN PHARMACEUTICAL HANGZHOU CO LTD
    Active DMF 27202 · latest filing Jun 2013
    CEP
  • JOYANG LABORATORIES
    Active DMF 31225, 34630 · latest filing Mar 2020
    ChinaCEP
  • NORTH CHINA PHARMACEUTICAL HUASHENG CO LTD
    Active DMF 34270 · latest filing Mar 2020
    ChinaCEP Company GMP cert on record
  • TAPI NL BV
    Active DMF 28524 · latest filing Aug 2014
    NetherlandsCEP
  • Wuxi Fortune Pharmaceutical Co., Ltd.
    Active DMF 39816 · latest filing Jun 2024
    ChinaCEP Company GMP cert on record
  • Apotex Inc.
    Active DMF 28065 · latest filing Mar 2014
    Canada
  • Astellas Pharma Inc.
    Active DMF 16833 · latest filing Sept 2003
    Japan Company GMP cert on record
  • CHENGDU YACHT BIO-TECHNOLOGY CO LTD
    Active DMF 40448 · latest filing Oct 2024
    China
  • CKD BIO CORP
    Active DMF 31097 · latest filing Oct 2016
    South
  • FARMHISPANIA SA
    Active DMF 35852 · latest filing Apr 2021
    Spain
  • FISHFA BIOGENICS (A DIV OF FISHFA RUBBERS LTD)
    Active DMF 39667, 41828 · latest filing Jun 2025
    India
  • FUJIAN KERUI PHARMACEUTICAL CO LTD
    Active DMF 21808 · latest filing Jul 2008
    China
  • Guangdong Blue Treasure Pharmaceuticals Co. Ltd.
    Active DMF 44366 · latest filing Jun 2026
    China
  • LUNAN NEW TIME BIO-TECH CO LTD
    Active DMF 37982, 38985 · latest filing Nov 2023
  • Fishfa Biogenics
    IndiaCEP
Need Tacrolimus sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (10)

Certificates of Suitability on the EDQM register for Tacrolimus, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 12 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
TAPI NL B.V. AmsterdamNL
CEP 2018-233 - Rev 07
Tacrolimus monohydrate
Apr 2026—
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Shu LinTW
CEP 2018-241 - Rev 03
Tacrolimus monohydrate
Feb 2026Inspected Apr 2024
Germany
FISHFA BIOGENICS RajkotIN
CEP 2023-394 - Rev 00
Tacrolimus monohydrate
Sept 2025—
CONCORD BIOTECH LIMITED AhmedabadIN
CEP 2020-227 - Rev 02
Tacrolimus monohydrate, Process II
Jul 2025Inspected Jul 2025
Germany
BIOCON LIMITED BengaluruIN
CEP 2017-257 - Rev 02
Tacrolimus monohydrate
Jun 2025—
HISUN PHARMACEUTICAL (HANGZHOU) CO., LTD. Hangzhou CityCN
CEP 2018-284 - Rev 02
Tacrolimus monohydrate
Oct 2024—
WUXI FORTUNE PHARMACEUTICAL CO., LTD. WuxiCN
CEP 2023-051 - Rev 00
Tacrolimus monohydrate
Sept 2024Inspected Mar 2025
Germany
JOYANG LABORATORIES YanchengCN
CEP 2021-210 - Rev 01
Tacrolimus monohydrate
Jul 2024Inspected Nov 2024
Germany
LEK PHARMACEUTICALS D.D. LjubljanaSI
R0-CEP 2021-204 - Rev 01
Tacrolimus monohydrate
Aug 2023—
North China Pharmaceutical Huasheng Co., Ltd. ShijiazhuangCN
R0-CEP 2021-180 - Rev 01
Tacrolimus monohydrate
Jun 2023—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (3)

Organisations whose Type II DMFs for Tacrolimus are no longer active. These show a past filing, not current supply.

Show all 3 historical records

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (58 listed products contain Tacrolimus). The latest listed patent expires 30 Aug 2028. The latest listed exclusivity runs to 16 Jul 2028. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Tacrolimus is an immunosuppressive drug primarily used to reduce the risk of organ transplant rejection. It acts by inhibiting T-lymphocyte activation.

Chemical identity

IUPAC name
(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-[(E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-prop-2-enyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone;hydrate
Canonical SMILES
C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC.O
InChIKey
NWJQLQGQZSIBAF-MLAUYUEBSA-N
Synonyms
Protopic API, advagraf, envarsus xr, fk-506, fk506, fr-900506, fr900506, modigraf, nsc-758659, prograf, protopic, tacrolimus hydrate

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Calcineurin Inhibitor Immunosuppressant
Mechanism of action
Calcineurin Inhibitors

Therapeutic areas

ImmunosuppressionTransplantation

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Tacrolimus?

19 organisations hold an active US FDA Type II Drug Master File or a CEP for Tacrolimus: Biocon Limited (India), CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTD, CONCORD BIOTECH LTD (India), Lek Pharmaceuticals D.D. (Slovenia), HISUN PHARMACEUTICAL HANGZHOU CO LTD, JOYANG LABORATORIES (China), NORTH CHINA PHARMACEUTICAL HUASHENG CO LTD (China) and TAPI NL BV (Netherlands), and 11 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Tacrolimus Drug Master Files are active?

Biocon Limited (DMF 39573, 18442), CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTD (DMF 18985, 38310), CONCORD BIOTECH LTD (DMF 18908, 34491), Lek Pharmaceuticals D.D. (DMF 19979, 34063), HISUN PHARMACEUTICAL HANGZHOU CO LTD (DMF 27202), JOYANG LABORATORIES (DMF 31225, 34630), NORTH CHINA PHARMACEUTICAL HUASHENG CO LTD (DMF 34270) and TAPI NL BV (DMF 28524) and 10 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Tacrolimus records mean?

3 organisations have only inactive Type II DMFs for Tacrolimus. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Tacrolimus have a European Certificate of Suitability?

Yes. 10 organisations hold a valid CEP for Tacrolimus on the EDQM register, including TAPI NL B.V. Amsterdam (NL), Chunghwa Chemical Synthesis & Biotech Co., Ltd. Shu Lin (TW), FISHFA BIOGENICS Rajkot (IN), CONCORD BIOTECH LIMITED Ahmedabad (IN), BIOCON LIMITED Bengaluru (IN) and HISUN PHARMACEUTICAL (HANGZHOU) CO., LTD. Hangzhou City (CN) and 4 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Tacrolimus?

Yes. The latest patent listed for an approved US product containing Tacrolimus expires 30 Aug 2028, across 58 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Tacrolimus supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Tacrolimus?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.